Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Hun Ju Lee, Jeremy S. Abramson, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Domingo Domenech Eva, Brian T. Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Giuseppe Rossi, Uwe H Hahn, Henry Miles Prince, Linda Ho, Wenchuan Guo, Christopher A. Yasenchak, David J. Straus
Institutions: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Washington University in St. Louis, Rocky Mountain Cancer Centers, University of Washington, Fred Hutch Cancer Center, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Duran i Reynals Hospital, Medical University of South Carolina, MUSC Hollings Cancer Center, Poudre Valley Hospital, University of Tennessee Medical Center, Virginia Cancer Specialists, Toledo Clinic Cancer Center, Toledo Clinic Cancer Center, University of Utah, Huntsman Cancer Institute, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Queen Elizabeth Hospital, Seagen (United States), Willamette Valley Cancer Institute and Research Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310103707